NexgenRx Inc.
TSX VENTURE : NXG

NexgenRx Inc.

April 05, 2012 15:43 ET

NexgenRx Announces Debenture Issuance

TORONTO, ONTARIO--(Marketwire - April 5, 2012) - NEXGENRX INC. (TSX VENTURE:NXG) ("NexgenRx" or the "Corporation") is pleased to announce that it has issued a convertible debenture in the aggregate principal amount of $500,000 (the "Debenture"). The Debenture has been issued to an arm's length party and is convertible (in whole or in part) into common shares in the capital of the Corporation at a price of $0.30 on or before November 26, 2013. The Debenture and any securities issuable upon conversion thereof is subject to a four-month hold period in accordance with applicable securities laws, which will expire on August 5, 2012. The Debenture is being issued as replacement for the Corporation's previously issued convertible debenture in the principal amount of $500,000, which was initially issued in April 2007 and matured and came due in November 2011.

About NexgenRx

NexgenRx is a growing health benefits management company engaged in the design, management and administration of health benefit plans offered by employers and other plan sponsors for the benefit of their employees and plan members. More information on NexgenRx can be found at www.nexgenrx.com.

Caution Regarding Forward-Looking Statements - This news release contains certain forward-looking statements, including statements regarding the business and anticipated financial performance of the Corporation. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Contact Information

  • NexgenRx Inc.
    Ronald C. Loucks
    President and CEO
    (416) 695-3393 x 801
    (647) 722-2920 (FAX)
    www.nexgenrx.com